Total
0
Shares
Medicenna (TSX:MDNA) posts $2.3M net loss for Q2
  • Resverlogix has announced findings from a recent publication that analyzed one of the company's products
  • Apabetalone, a BET (bromodomain and extra-terminal) inhibitor, was discussed in the peer-reviewed Cardiovascular Diabetology publication
  • When total hospitalizations for heart failure were analyzed, apabetalone treatment demonstrated a significant 53 per cent hazard reduction
  • The company will be including hospitalizations for heart failure in the composite primary endpoint for its upcoming registration-enabling study, BETonMACE2
  • Resverlogix is up 1.12 per cent to $C0.90 per share

Resverlogix (RVX) has announced findings from a recent publication that analyzed one of the company's products.

Apabetalone, a BET (bromodomain and extra-terminal) inhibitor, was discussed in the peer-reviewed Cardiovascular Diabetology publication.

Dr. Stephen J. Nicholls, a lead author of the paper, said in the analysis from the BETonMACE study, significantly fewer hospitalizations for heart failure in patients with type 2 diabetes and a recent history of acute coronary syndrome were observed in the apabetalone treatment group compared to a placebo.

Another highlight from the study included that when total hospitalizations for heart failure were analyzed, apabetalone treatment demonstrated a significant 53 per cent hazard reduction.

Resverlogix President and CEO Donald McCaffrey said “the unprecedented reduction in heart failure seen in BETonMACE further demonstrates the broad benefit these patients receive from apabetalone treatment”.

McCaffrey added that in agreement with the US FDA, the company will be including hospitalizations for heart failure in the composite primary endpoint for its upcoming registration-enabling study, BETonMACE2.

The publication concluded that despite current standard of care treatment options, patients with diabetes and acute coronoary syndrome (ACS) have a high risk of experiencing subsequent cardiovascular events, including those related to congestive heart failure.

This prespecified analysis, illustrated that treatment with apabetalone following an ACS was associated with a lower incidence of hospital admission for heart failure. This finding provides the rationale to further explore apabetalone’s effect on hospitalizations for heart failure and highlights a potential new therapeutic strategy to benefit these high-risk patients.

Resverlogix is developing apabetalone, a first-in-class, small molecule that is a selective BET inhibitor.

Apabetalone is the first therapy of its kind to have been granted US FDA Breakthrough Therapy Designation, for a major cardiovascular indication, to help facilitate a time-efficient drug development program including planned clinical trials and plans for expediting the manufacturing development strategy.

Resverlogix is up 1.12 per cent to $C0.90 per share at 3:40pm EST.


Subscribe


More From The Market Herald
Cipher Pharma report $3 million turnaround in 2019

" PharmaTher (CSE:PHRM) signs license agreement for patented Ketamine formulation targeting mental health

PharmaTher (PHRM) has signed an exclusive worldwide license agreement for a patented ketamine formulation.
Nutritional High’s upcoming acquisition enters research agreement

" Theratechnologies (TSX:TH) raises over $58M in public offering

Biopharmaceutical company Theratechnologies (TH) has closed its bought deal public offering after raising over C$58 million in proceeds.
TAAT Lifestyles & Wellness (CSE:TAAT) hires new U.S. patent attorney with Fortune 100 experience

" TAAT Lifestyles & Wellness (CSE:TAAT) hires new U.S. patent attorney with Fortune 100 experience

TAAT Lifestyle & Wellness (TAAT) has hired U.S. patent attorney Edmond DeFrank to secure its intellectual property.
MCI Onehealth (TSXV:DRDR) expands digital health footprint

" MCI Onehealth (TSXV:DRDR) expands digital health footprint

MCI Onehealth (DRDR) is accelerating its digital health adoption initiative by acquiring a series healthcare technologies and clinics.